BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance
The BCR/ABL fusion gene is formed by reciprocal translocation t(9;22)(q34;q11), resulting in an abnormally short derivative chromosome 22 (22q-), which is known as the Philadelphia chromosome. At the molecular level, the translocation (gene rearrangement) results in fusion of BCR gene coding sequences to ABL gene coding sequences. The resultant chimeric gene and fusion transcript encode a fusion protein with constitutively activated tyrosine kinase activity, suggested to be responsible for the development of certain leukemias. Approximately 95% of cases of chronic myelogenous leukemia (CML) have the characteristic t(9;22)(q34;q11). The remaining cases either have an unidentifiable translocation between 9q34 and 22q11 that cannot be identified by routine cytogenetic analysis, or have variant translocations involving a third or even a fourth chromosome besides 9 and 22. Also, a subset of acute lymphoblastic leukemia cases and a smaller subset of acute myelogenous leukemia cases have been shown to have the Bcr/Abl translocation.
The most effective course of treatment of Philadelphia chromosome-positive (Ph-positive) leukemias such as CML is the drug Gleevec. Gleevec, also known as imatinib, is a Bcr/Abl tyrosine kinase inhibitor that inhibits tyrosine kinase activity by binding to the active site of the enzyme. Gleevec is effective in Philadelphia chromosome–positive (Ph-positive) leukemias (e.g., CML), but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with bcr/abl mutations that interfere with imatinib binding. The bcr/abl mutation analysis is used to monitor treatment as well as evaluate the effectiveness of Gleevec. The analysis involves direct DNA sequencing of the PCR-amplified bcr/abl products. The sequence is then compared with an Abl kinase domain reference sequence to identify single or multiple mutations. Mutations at 17 different amino acid positions within the Bcr-Abl kinase domain have been associated with clinical resistance to imatinib. Patients with T315I mutation are resistant to both imatinib and dasatinib.
- To detect Ph chromosome positive leukemias resistant to standard Gleevec therapy
- To monitor the treatment and effectiveness of the drug Gleevec in the treatment of CML and other leukemias (such as precursor B lymphoblastic leukemia) that carry Bcr/Abl translocation
Positive in:
- Imatinib-resistant Ph-positive chronic myeloid leukemia
- Imatinib-resistant Ph-positive precursor B lymphoblastic leukemia
Negative for Imatinib-resistance analysis
Whole Blood EDTA (Lavender), Bone Marrow EDTA (Lavender)
Stability
- Ambient: 1-3 days
- Refrigerated: 7 days
- Frozen: Unacceptable
- Expert Rev Anticancer Ther. 2012 Mar;12(3):381-92. [PMID: 22369329] Science. 2004;305:399. [PMID: 15256671]
- N Engl J Med. 2006;354:2531. [PMID: 16775234]
- J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. [PMID: 17970609]
- Leukemia. 1996 May;10(5):751-6. [PMID: 8656667]